There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Embecta ...

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

BeiGene Ltd ( ($HK:6160) ) has issued an announcement. BeiGene Ltd., a biopharmaceutical company, announced the grant of share options and ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

Shares of Immunitybio rose 9.81 percent on Thursday to finish at $3.47 apiece as investor sentiment was buoyed by news that ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Energy equipment manufacturer GE Vernova saw its share prices grow by 8.42 percent on Thursday to close at $382.94 apiece as ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...